

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 2, second paragraph:

In previous patent applications [EPA-0347856] EPA-0347056 and EPA-0599576 we have drawn attention to the action of various essential fatty acids in schizophrenia and have claimed the use of these fatty acids in treatment. We have particularly drawn attention to the low red cell levels of arachidonic acid (AA) and docosahexaenoic acid (DHA) and to the use of these fatty acids.